HOME >> MEDICINE >> NEWS
Leading immunosuppressant CellCept significantly extends the lifespan of transplanted kidneys

The analysis showed that after three years treatment with CellCept + tacrolimus, kidney survival was 85.9% versus 80.3% with patients taking sirolimus + tacrolimus immunosuppressants. The outcome was even better for higher risk patients with a kidney survival rate of 74.5% vs 57.5%[i]. The new data were presented at the European Society for Organ Transplantation (ESOT), Geneva, Switzerland. Previous data have shown that CellCept gives a survival benefit when compared to older immunosuppressant drugs and now these new data demonstrate the survival benefit of CellCept combinations over the newer drug regimens.

Kidneys are the most commonly transplanted organs[ii]; for every kidney available there are four people waiting to receive one[iii]. After transplantation, people need to take a combination of immunosuppressant drugs for the rest of their lives to prevent the body rejecting the new organ. By preserving the transplanted organ with CellCept based combinations, doctors can help patients to keep their organs longer, thereby, reducing the burden on the already limited donor pool. One way to achieve this is by choosing combinations based on the low toxicity profile of CellCept, along with reduced doses of the more toxic immunosuppressant drugs to decrease the risk of losing the new kidney.

"We have learnt that the combination of cyclosporine/sirolimus is toxic to the kidney over time and as a result some doctors have switched to a sirolimus/tacrolimus combination, that was perceived to be less toxic," said Prof Herwig-Ulf Meier Kriesche, University of Florida, Gainesville, Fl, USA. "Now we have the data to show that this combination is just as damaging. These data, along with this latest analysis of patients on CellCept combinations, should help us make an evidence-based choice on how best to reduce the risk of toxicity, which we know is associated with some long-term immunosuppressant regimens," he added.


'"/>

Contact: Helen Swift
helen.swift@ketchum.com
+44-20-7611-3637
Ketchum
19-Oct-2005


Page: 1

Related medicine news :

1. Leading prevention researchers meeting in Washington, D.C., May 30-June 1, 2007
2. Leading advocates express support for microbicide research, despite disappointing trial results
3. Leading European experts in magnetic resonance for animals
4. Leading healthcare authorities to address safety and effectiveness
5. Leading international osteoporosis experts to present at worlds largest osteoporosis congress
6. Leading hepatology textbook edited by SLU researchers
7. Leading groups offer NIH direct links to journals to make research access easy for public
8. Leading pediatricians group recommends infants sleep in cribs, not parents beds
9. Leading genomic technology expert to present Dickson Prize Lecture at Pitt
10. Leading experts discuss how to protect premature infants against RSV, a potentially dangerous virus
11. Leading sleep expert at Wake Forest to speak at NIH Consensus Conference

Post Your Comments:
(Date:7/24/2014)... 25, 2014 The report, “Content ... CDN market into various sub-segments with an in-depth ... the drivers and restraints for this market with ... 93 market data tables and 36 figures spread ... Delivery Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... In a July 9th article in the Money magazine ... Blossom Consulting LLC , was quoted in a Family Finance ... the High Cost of Infertility . Her advice began with, ... your chance of success from the first attempt.” The article ... “I am always happy to talk with the media about ...
(Date:7/24/2014)... Kathleen Doheny HealthDay Reporter ... of obese children often don,t view their kids as unhealthy ... according to a new study. The children of the ... clinic at the Hasbro Children,s Hospital in Providence, R.I. ... good," said study researcher Dr. Kyung Rhee, now an assistant ...
(Date:7/24/2014)... and obese preschoolers works better when treatment targets both ... is targeted, according to research published this week in ... Buffalo and Women and Children,s Hospital of Buffalo., Children ... had one parent who participated in the study who ... index (BMI) measurements, calculated based on height and weight., ...
(Date:7/24/2014)... material like a medical device or surgical implant is ... According to Northwestern University,s Guillermo Ameer, most of the ... device,s function. , "You will always get an inflammatory ... engineering in Northwestern,s McCormick School of Engineering and Applied ... of Medicine. "A problem with commonly used plastic materials, ...
Breaking Medicine News(10 mins):Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Antioxidant biomaterial promotes healing 2
(Date:7/24/2014)... SOUTH PLAINFIELD, N.J. , July 24, 2014 /PRNewswire/ ... announced that the Company will host a webcast conference ... and provide an update on the company,s business and ... (ET) before the opening of the market. ... 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
Cached News: